Ecoprin

Quick links to important sections

Ecoprin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ecoprin

Quick Facts

Property Description
Active Ingredient Acetylsalicylic acid (ASA)
Form Enteric-coated tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID); Antiplatelet Agent
Common Use Cardiovascular prophylaxis
Origin Synthetic

What Type of Medicine is Ecoprin?

Ecoprin is a pharmaceutical preparation containing the active ingredient Acetylsalicylic acid (ASA), which is widely known generically as Aspirin. This medication is classified under two distinct pharmacological groups: the Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and, fundamentally, the Antiplatelet Agents. ASA is manufactured synthetically as a derivative of salicylic acid. Unlike standard NSAIDs, ASA's unique action—specifically its irreversible antiplatelet effect—is clinically recognized for altering the blood clotting process. This singular feature differentiates it from typical pain relievers and underpins its primary role in long-term prophylactic care.

Composition and The Enteric-Coated Form

Ecoprin is supplied as an oral dosage form in the shape of a tablet. It contains the active substance, Acetylsalicylic acid, along with excipients and a specialized polymeric enteric coating. This coating is a differentiating feature of Ecoprin's composition: it is purposefully designed to resist the high acidity of the stomach. Enteric coating technology is used to prevent gastric irritation or to ensure the medicine reaches the small intestine. This delayed dissolution helps improve the medicine's gastric tolerability, an essential factor for patients who take the medicine regularly for cardiovascular health management.

Ecoprin's General Purpose

The general purpose of Ecoprin is to influence the body’s clotting system to help maintain blood fluidity. By minimizing the tendency of platelets to aggregate, Ecoprin functions as a primary agent in cardiovascular prophylaxis, often used in scenarios where reducing the risk of undesirable clot formation is necessary. Secondarily, as an NSAID, the medication also helps to generally relieve mild pain and reduce fever and generalized inflammation by interfering with the synthesis of key chemical messengers, such as prostaglandins, that mediate these physiological responses.

What side effects are possible with Ecoprin?

Possible Side Effects and Safety Information

The following information is based on official government regulatory documents regarding the safety profile of Ecoprin (acetylsalicylic acid).

Serious Adverse Reactions and Restrictions

The primary serious risks associated with this medicine are related to bleeding events and severe allergic reactions.

  • Bleeding Risks: Serious adverse reactions include major gastrointestinal bleeding, ulceration, and perforation, which can be fatal, and intracranial hemorrhage (bleeding in the brain). These risks may be increased with long-term use.
  • Hypersensitivity: Rare but serious allergic reactions, including anaphylactic shock and severe skin reactions like Stevens-Johnson Syndrome, are documented. Use is restricted in patients with known allergy to aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and in those with aspirin-induced asthma.

Population-Specific Safety Considerations

Population Regulatory Restriction/Safety Note
Children/Adolescents Contraindicated for use in children and teenagers (typically under 16 or 18) for fever or viral illnesses, such as chickenpox or flu symptoms, due to the documented risk of Reye's Syndrome, a rare but serious condition.
Pregnancy Contraindicated in the third trimester (last three months) of pregnancy due to risks of fetal cardiovascular complications (premature closure of the ductus arteriosus) and potential complications during delivery.
Elderly Use with caution due to a documented increased susceptibility to adverse effects, particularly the risk of bleeding.

Commonly Documented Adverse Reactions

Adverse reactions that are reported as common (occurring in 1% to 10% of users) primarily involve the gastrointestinal system and general bleeding, such as gastrointestinal hemorrhage, dyspepsia (indigestion), epistaxis (nosebleeds), and haematoma (bruising).

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented overdose manifestations and mandated emergency actions for acetylsalicylic acid (Ecoprin), as outlined in government regulatory information.


Documented Manifestations and Outcomes

Classification Official Regulatory Description
Early Signs Tinnitus (ringing in the ears), hyperventilation (rapid breathing), nausea, vomiting, dizziness, and sweating are commonly documented initial signs.
Severe Outcomes Toxicity can lead to severe metabolic acidosis, central nervous system (CNS) effects like confusion, seizures, cerebral edema, and coma. Life-threatening cardiopulmonary and renal failure may also occur.
Management Note The treatment approach is defined as symptomatic and supportive, as regulatory information states that no specific antidote is known for salicylate poisoning.

When to Seek Urgent Medical Help

Official government guidance mandates that an individual contact a Poison Control Center immediately and seek immediate medical attention upon suspected overdose. Urgent hospitalization is required when signs of severe toxicity are present, including the development of CNS symptoms, severe systemic metabolic acidosis, or noncardiogenic pulmonary edema. Management procedures may involve the administration of activated charcoal, correction of acid-base disturbances, and advanced methods like hemodialysis for severe cases. Both young children and older adults are noted as populations with increased vulnerability to the severe effects of overdose.

Therapeutic Uses of Ecoprin

What Ecoprin Treats: Main Uses and Benefits

This section explores the therapeutic applications and benefits of Ecoprin.

The medication Ecoprin, containing acetylsalicylic acid (ASA), is commonly used across two main therapeutic domains.

Ecoprin is relevant in contexts where supportive symptom management is appropriate and may assist in reducing the likelihood of major cardiovascular events. It is applied across domains where patients experience conditions associated with acute or disruptive episodes, such as a prior heart attack, ischemic stroke, or TIA (mini-stroke). This long-term use supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load by supporting the body during vascular treatment after procedures like stenting.

In addition to its role in cardiovascular prophylaxis, Ecoprin may be applied in addressing symptoms related to acute systemic distress. It is commonly used for temporary, short-term management of symptoms related to physical discomfort, including common headaches and body aches, and to manage fever (elevated body temperature).

“The medication is applied in both contexts involving long-term preventative care and those requiring temporary symptomatic support.”

Quick Facts: Therapeutic Focus

  • Cardiovascular Focus: May assist in reducing the likelihood of major vascular events in patients at high risk.
  • Symptomatic Focus: Used for managing symptoms related to physical discomfort and acute systemic distress (fever).
  • Inflammatory Support: Applied in conditions involving inflammatory or irritative processes to help ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Ecoprin (Acetylsalicylic acid/ASA) eligibility is strictly governed by regulatory documentation, which defines both approved users and populations that are contraindicated or require special caution.

Official Eligibility Rules

Category Official Regulatory Status
Populations for Whom Use is Allowed Adults for long-term cardiovascular prophylaxis [SmPC: 4.1].
Populations for Whom Use is Contraindicated Patients with known hypersensitivity to ASA or NSAIDs, active peptic ulcer or internal haemorrhage, or established coagulation disorders [SmPC: 4.3]. Contraindication also applies to patients with severe hepatic, renal, or uncontrolled cardiac insufficiency [SmPC: 4.3].
Age-Related Eligibility Rules Not recommended for children and adolescents under 16 years of age due to the association with the risk of Reye's syndrome [SmPC: 4.4]. Older adults are eligible but should be monitored with caution [SmPC: 4.4].
Pregnancy and Lactation Status Contraindicated during the third trimester of pregnancy at doses ge 100 mg/day [SmPC: 4.3]. Not recommended while breastfeeding [SmPC: 4.6].
Condition-Specific Restrictions Use requires caution in patients with a history of asthma, moderate organ impairment (hepatic/renal), or a history of gastric ulceration [SmPC: 4.4]. Contraindicated in patients receiving Methotrexate at doses > 15 mg/week [SmPC: 4.3].

Eligibility Summary

Official prescribing information defines use based on minimizing bleeding risk and adverse effects in vulnerable groups. The absolute prohibition for use is tied to specific conditions that elevate hemorrhagic risk or compromise the body’s ability to clear the drug, while age-related restrictions are based on the documented risk of Reye's syndrome.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Ecoprin (Aspirin) interacts with several drug classes, primarily due to additive effects on bleeding risk and gastrointestinal integrity, as documented in official regulatory labeling.

Clinically Significant Interactions

Interacting Product Category Documented Interaction Constraint
Anticoagulants (e.g., Warfarin, Heparin) Increased risk of hemorrhage due to additive effects on hemostasis. Co-administration requires caution.
Other Antiplatelet Agents (e.g., Clopidogrel) Increased risk of bleeding events.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of gastrointestinal bleeding and ulceration.
Ibuprofen May interfere with aspirin's antiplatelet effect. Doses may require specific temporal separation (e.g., taking aspirin at least 2 hours before ibuprofen).
Methotrexate Aspirin may increase the plasma concentration and potential toxicity of methotrexate by competing for renal excretion.
Uricosuric Agents (e.g., Probenecid) Aspirin may diminish the therapeutic effect of these medicines against gout.

Other Documented Interactions

  • Alcohol: Consumption of three or more alcoholic drinks daily may significantly increase the risk of severe gastrointestinal bleeding when combined with aspirin.
  • Population Note: Use in children and teenagers recovering from viral infections (e.g., chickenpox, flu) is associated with the risk of Reye’s Syndrome.

Mechanism of Action

How Ecoprin Works

Ecoprin (Acetylsalicylic acid) acts as a unique, irreversible modulator of key regulatory enzymes within the body's communication pathways. Its mechanism operates across three principal domains: permanent anti-clotting action, suppression of inflammation, and central temperature modulation.


Irreversible Antiplatelet Function

This primary domain involves the covalent and permanent deactivation of the Cyclooxygenase-1 ( COX-1) enzyme, particularly within circulating platelets. Since platelets lack the ability to synthesize new enzyme, this blockade is sustained for the platelet's lifespan. The molecular consequence is a functional and prolonged suppression of Thromboxane A2 ( TXA2) synthesis, resulting in a diminished capacity of blood components for aggregation.


Systemic Eicosanoid Modulation

Ecoprin engages a secondary domain by inhibiting COX enzymes in peripheral tissues, which suppresses the production of various prostaglandins ( PGE2) that mediate pain and inflammation. This action modifies biochemical signals that cause tissue sensitization and swelling. The central component of this domain involves the reduction of PGE2 in the hypothalamus, which alters the body's thermoregulatory set-point.


Mechanistic Constraints

The anti-clotting mechanism's effectiveness relies entirely on its irreversible binding to COX-1. However, the effects stemming from COX-2 inhibition are reversible in nucleated cells, meaning the functional duration of these effects is constrained by the cell's capacity for enzyme regeneration.

Dosage and Administration Information

How Ecoprin is Used: Administration Guidelines

The usage of Ecoprin, an enteric-coated form of Acetylsalicylic acid (ASA), is defined by instructions to ensure proper administration and function. The medication is intended for oral administration only. Its administration protocol is distinguished by the therapeutic purpose, governing both the dose and frequency.


Dosing and Frequency Patterns

Administration Focus Standard Labeled Regimen Frequency Pattern
Long-term Prophylaxis 75 mg to 162.5 mg Once Daily
Short-term Symptomatic Relief 325 mg to 650 mg per dose Every 4 to 6 hours, up to 4 g daily

Administration Requirements

As an enteric-coated tablet, the drug's intended action depends on the medicine passing through the stomach intact. Therefore, the tablet must be swallowed whole with a full glass of water and must not be crushed, split, or chewed.

The dose is generally taken with or immediately following food to aid gastric tolerability. For adults on long-term daily use, if a dose is missed, it should be taken when remembered, but double doses are not permitted to compensate.

Population-Specific Constraints

Labeling generally restricts the use of this medication in children and adolescents under 16 years of age, unless administration is directed by a healthcare professional. These instructions define a standardized protocol for the administration of Ecoprin across its approved uses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

How Clinical Studies Evaluate This Treatment

Ecoprin contains a low dose of acetylsalicylic acid (aspirin) and is studied primarily for its antiplatelet effects, which inhibit the formation of blood clots. Research trials examined the effects of the treatment on the risk of major cardiovascular events over time in adult populations. The drug’s evaluation consistently involves randomized, placebo-controlled trials (RCTs).


Key Findings from Major Trials

Prevention of Cardiovascular Events

Major international studies have assessed the use of Ecoprin for primary and secondary prevention of cardiovascular events. The most notable finding across several large trials is that low-dose aspirin was associated with a reduction in the risk of non-fatal myocardial infarction (heart attack) in individuals at risk.

  • Myocardial Infarction: The primary outcome measure in key trials indicated that a reduction in heart attack risk was observed in participants receiving the treatment compared to the placebo group. Study follow-up data has consistently supported this finding.
  • Ischemic Stroke: Researchers examined whether the treatment was associated with a reduction in the risk of ischemic stroke (clot-related stroke). Findings related to hemorrhagic stroke (bleeding-related stroke) sometimes indicated a slightly increased trend in risk, requiring careful balancing of potential effects.

Safety and Tolerability

The available evidence reported safety and tolerability in the studied populations, which is often a key consideration in long-term preventive use.

  • Common Adverse Events: The most frequently reported events included common gastrointestinal issues such as indigestion, nausea, and heartburn. The trials reported that these events were often mild.
  • Serious Events: A main risk factor examined in studies is the increased tendency for bleeding, including gastrointestinal bleeding. The serious adverse event rates were reported in the studies and must be weighed against the benefit of preventing blood clots.

Key Studies & References

  1. LOW DOSE ASPIRIN - aspirin tablet, delayed release (U.S. Food and Drug Administration / DailyMed)
  2. NICE guideline [CG181] - Cardiovascular disease: risk assessment and reduction, including lipid modification (Used for general clinical context/risk-benefit summary)

Frequently Asked Questions (FAQ)

Common questions about Ecoprin (FAQ)

Q: How quickly does Ecoprin start working?

A: According to official product information, the initial effects of the active ingredient, acetylsalicylic acid (ASA), for managing pain or fever typically begin within 30 minutes. The primary benefit of Ecoprin, its irreversible antiplatelet effect (the ability to inhibit blood clotting), is understood to begin working rapidly after administration.


Q: Do I need a prescription to buy Ecoprin?

A: In many regions, low-dose acetylsalicylic acid (ASA) products are often available for purchase without a prescription (Over-The-Counter or OTC). However, regulatory status can depend on the specific strength or formulation, and some higher doses or specialized products may be designated as prescription-only.


Q: Does Ecoprin interact with blood pressure medicine?

A: Official labeling indicates that acetylsalicylic acid (ASA) may potentially reduce the blood pressure-lowering effects of some medicines used to treat high blood pressure, such as ACE inhibitors. This potential interaction is primarily noted in regulatory documents at higher ASA doses.


Q: Are there studies about Ecoprin's use in healthy people?

A: Regulatory guidance and official clinical guidelines focus on the use of low-dose ASA primarily for the prevention of cardiovascular events in patients who are considered to be at risk of conditions like heart attack or stroke. Research themes and clinical guidelines often emphasize populations considered 'at-risk' for cardiovascular events.


Q: Can Ecoprin interact with herbal supplements?

A: While specific interaction data on every single herbal supplement is not listed, official patient information often reminds that patients disclose all products, including herbal remedies or supplements, to their healthcare provider. This is because some supplements may affect blood clotting or otherwise interact with Ecoprin’s active ingredient.


Q: What if I need surgery while taking Ecoprin?

A: Official warnings about Ecoprin reference the potential for increased bleeding risk due to its antiplatelet effect. The decision to continue or temporarily stop Ecoprin before a surgical procedure is a determination made by a healthcare professional, based on balancing the risk of bleeding versus the risk of a blood clot event.


Q: What is the maximum amount of time someone can take Ecoprin?

A: The active ingredient in Ecoprin, ASA, is officially indicated for long-term use in cardiovascular prevention. Official labeling describes its use for specific indications, such as following certain medical events, but regulatory documents do not define a strict maximum duration limit for continuous long-term preventive use.


Q: Is Ecoprin still being studied for new uses?

A: Research into new potential uses for aspirin (the active ingredient in Ecoprin) is an ongoing process in the medical and scientific community. These studies often explore the drug's effects beyond blood thinning, but any new uses are considered investigational until they receive official regulatory approval.


Q: Is it true that Ecoprin can cause ringing in the ears?

A: Official safety documents confirm that ringing in the ears, also known as tinnitus, or a loss of hearing can occur with the use of acetylsalicylic acid. Regulatory documents recommend that individuals experiencing this symptom contact a healthcare provider.


Q: Do I need to stop taking Ecoprin before a dental procedure?

A: The decision regarding stopping Ecoprin before minor procedures, such as dental work, depends on the individual patient's risks. Official information indicates that the determination of whether to continue or stop Ecoprin for minor procedures is the responsibility of the treating clinician.


Q: Is Ecoprin the same as standard aspirin?

A: Ecoprin contains the active ingredient acetylsalicylic acid (ASA), which is the same as generic aspirin. The product is primarily distinguished by its enteric-coated formulation and its intended use for cardiovascular protection at specific low doses, unlike the often higher doses used for general pain and fever relief.


Q: Why is Ecoprin often described as 'low dose'?

A: The term 'low dose' is used because the typical amount of active ingredient for long-term preventive use is much lower than the amounts typically required to relieve pain, fever, or inflammation. This specific, smaller dose is sufficient to achieve the antiplatelet (anti-clotting) effect.


Q: How long do the effects of Ecoprin last?

A: The irreversible antiplatelet effect of Ecoprin lasts for the lifespan of the affected platelet, which is about 7 to 10 days. Other benefits of the medicine, such as pain or fever relief, are based on a different mechanism that is reversible and therefore of shorter duration.


Q: What types of foods or drinks should be avoided while using Ecoprin?

A: Official safety information specifically warns that consuming three or more alcoholic drinks daily may significantly increase the risk of severe gastrointestinal bleeding when combined with Ecoprin’s active ingredient. Official labeling does not list specific food restrictions.


Q: Are there any long-term effects of taking Ecoprin regularly?

A: When taken regularly over a long period, there is a documented potential for the risk of serious adverse reactions to be increased. Official documents note that this primarily includes a heightened risk of major gastrointestinal bleeding and ulceration.


Q: Is there a generic version of Ecoprin?

A: The active ingredient in Ecoprin is acetylsalicylic acid (ASA), which is the generic name for aspirin. ASA is a widely available generic drug that can often be found in the same enteric-coated formulation.


Q: How is Ecoprin different from other blood thinners?

A: Ecoprin is classified as an antiplatelet agent, meaning it works by directly inhibiting the clumping of blood cells called platelets. This mechanism is distinct from that of anticoagulants (or 'true blood thinners'), which operate by altering the blood clotting factors.


Q: Is Ecoprin linked to an increased risk of stroke?

A: Official clinical studies indicate that Ecoprin is associated with a reduced risk of ischemic stroke (a clot-related stroke). When balancing the effects, however, a slightly increased trend in the risk of hemorrhagic stroke (a bleeding-related stroke) has also been observed.


Q: Does Ecoprin affect kidney function?

A: Regulatory documents indicate that Ecoprin is generally restricted or requires caution in patients with severe kidney (renal) insufficiency. Additionally, the medicine can affect how certain other medications are processed by the kidneys.


Q: Are there different strengths of Ecoprin available?

A: The active ingredient in Ecoprin, acetylsalicylic acid (ASA), is commonly available in multiple strengths in various dosage forms. These often include a low dose (such as 75 mg or 81 mg) and a regular strength dose (such as 325 mg). The appropriate strength depends on the intended use.


Q: Why is the timing of taking Ecoprin sometimes important?

A: Timing is important for two reasons noted in the official information. First, taking the medicine with food can help gastric tolerability. Second, a specific time separation may be required when taking it alongside other common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen to help protect Ecoprin’s antiplatelet effect.


Q: Has Ecoprin been approved by the FDA?

A: The active ingredient, Acetylsalicylic acid (ASA), is a long-established and government-approved drug. Ecoprin complies with the official labeling and regulatory standards of government bodies, as referenced in documents like FDA DailyMed.


Q: How common are serious side effects with Ecoprin?

A: Official regulatory documents indicate that serious side effects, which include major bleeding events and severe allergic reactions, are generally listed as rare or infrequently reported. The likelihood of these events is a key factor considered in the decision for long-term use.

How should Ecoprin be stored and disposed of?

Storage and Disposal of Ecotrin (Aspirin)

Ecotrin tablets must be stored at Controlled Room Temperature, specifically 25 C (77 F), with limited excursions permitted between 15 C to 30 C (59 F to 86 F). The regulatory labeling requires protection from excessive heat and humidity and specifies that the product must be kept out of reach of children.

Stability and Handling

  • Container Integrity: Do not use the product if the printed inner-seal beneath the cap is missing or broken.
  • Degradation Check: The medicine must be discarded if it has developed a strong vinegar-like smell, which indicates the decomposition of the acetylsalicylic acid.

Official Disposal Protocol

Unused or expired Ecotrin should be returned using an official drug take-back program when available. If a take-back option is not accessible, the product may be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before disposal in household trash. Personal information must be removed from the original packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ecoprin found in:

A-Z Index: